Etiology and pathogenesis of inflammatory bowel diseases

Czech version

Authors: Milan Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE Lighthouse a 1. LF UK, Praha, přednosta prof. MUDr. Milan Lukáš, CSc.
Published in: Vnitř Lék 2014; 60(7-8): 640-644
Category: 100th Birthday - prof. Z. Mařatka

Overview

Zdenek Mařatka has been the first physician, who had brought a new information for the Czech medical community with topic of inflammatory bowel diseases, which had been systematic studied for him. He had prepared an original theory – two component hypothesis about origin of ulcerative colitis, which had been developed and innovated by him for long time. From the international point of view, Mařatka has had an extraordinary impact and significant contribution for recognition of ulcerative colitis and Crohn´s disease. Despite the fact that the true origin of ulcerative colitis and Crohn´s disease (UC) still remain elusive, basic as well as clinical research bring many new data on etiology and pathogenesis of this inflammatory condition. It seems clear that IBD originate from interaction of several intrinsic and extrinsic factors that contribute individually in a particular patient. Among internal factors the genes play an important role, because its influence on the mucosal immunity system and immunological response. Among the external factors importance are recognized the gut microbiota content, cigarette smoking and psychological stress.

Key words:
Crohn´s disease – etiology – pathogenesis – ulcerative colitis

Sources

1. Lakatos L, Lakatos LP. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006; 82(967): 332–337.

2. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122(1): 44–54.

3. Marteau P, Lepage P, Mangin I et a.l Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl 4): S18-S23.

4. Tamboli CP, Neut C, Desreumax P et al. Dysbiosis in inflammatory bowel disease. Gut 2004; 53(1): 1–4.

5. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 2011; 17(5): 557–566.

6. Pitcher MC, Beatty ER, Cumming JH. The contribution of sulphate reducing bacteria and 5-ASA to faecal sulphide in patients with ulcerative colitis. Gut 2000; 46(1): 64–72.

7. Cairo E. Toll-like receptors in inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16(9): 1583–1597.

8. Wekhmap J, Stange E. Paneht´s disease. J Crohns Colitis 2010; 4(5): 523–531.

9. Vermeire S, Rutgeerts P, Van Steen K et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistatis. Gut 2004; 53(7): 980–986.

10. Borm MEA, Van Bodegraven AA, Mulder CJJ et al. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005; 32(6): 401–405.

11. Franchimont D, Vermeire S, El Housni H et al. Deficient host‐bacteria interactions in inflammatory bowel disease? The toll‐like receptors (TLR)‐4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 2004; 53(7): 987–992.

12. Thompson AI, Lees ChW. Genetics of ulcerative colitis. Inflammm Bowel Dis 2011; 17(3): 831–848.

13. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18‐month follow‐up study. Psychosom Med 2004; 66(1): 79–84.

14. Bitton A, Sewitch MJ, Peppercorn MA et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroentrol 2003; 98(10): 2203–2208.

15. Tilg H, Kaser A. Diet and relapsing ulcerative colitis: take off the meat? Gut 2004; 53(10): 1399–1401.

16. Mařatka Z, Wágner V. The treatment of non-specific ulcerative colitis by autogenous vaccine; correlated bacteriological and immunological studies. Gastroenterology 1948; 11(1): 34–49.

17. Maratka Z, Spellberg MA. Observations on the clinical course of non-specific ulcerative colitis. Gastroenterology 1949; 12(1): 79–86.

18. Mařatka Z, Nedbal J, Kocianova J et al. Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years. Gut 1985 26(1): 43–49.

19. Mařatka Z. Colitis ulcerosa. Česká grafická unie: Praha 1948.

20. Mařatka Z. Pathogenesis and aetiology of inflammatory bowel disease. In: DeDombal FT, Myren J, Bouchier IAD et al (eds). Inflammatory bowel disease. Oxford University Press: Oxford 1993 (2nd ed).

21. Mařatka Z. The role of intestinal bacteria in the pathogenesis of inflammatory bowel diseases. A two‐component hypothesis. Folia Gastroenterol Hepatol 2003; 1: 6–11.

22. Rogler R. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004; 20(4): 311–317.

23. Rook GAW, Brunet LR. Chronic inflammatory disorders, the gut and “Old Friends” hypothesis. In: Colombel JF, Scholmerich J, Vucelic B (eds). Inflammatory bowel disease: translation from basic research to clinical practice. Falk Symposium Vol 140. Springer: Berlin 2005: 43–58. ISBN 978–1-4020–2847–2.

24. Frolkis A, Dieleman LA, Barkema H et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013; 27(3): e18-e24.

25. Ueno A, Jijon H, Traves Z et al. Opposing effects of Smoking in ulcerative colitis and Crohn´s disease may be explained by differencial effects on dendritic cells. Inflamm Bowel Dis 2014; 20(5): 800–810.

26. Mařatka Z Paměti. Karolinum: Praha 1997. ISBN 80–7184–077–7.